Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

86.4K
Overview
86.4K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Bilateral optic nerve head masses and retinopathy in a patient with B-cell acute lymphoblastic leukemia receiving CAR T-cell therapy masquerading as fungal endophthalmitis.

Frontiers in immunology·2026
Same author

Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients.

Blood immunology & cellular therapy·2026
Same author

Costimulation drives CAR-T cell division fate.

Nature immunology·2026
Same author

Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors.

Cytotherapy·2026
Same authorSame journal

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same author

Biomarkers for Diagnosis, Risk Stratification, and Immunotherapy of Pediatric Solid Tumors.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Resolution Biology in Soft Tissue Joint Disease.

Current topics in microbiology and immunology·2026
Same journal

A 25+ Year Journey on Yeast-Regulated Cell Death Research.

Current topics in microbiology and immunology·2026
Same journal

Resolution Pharmacology Targeting the Melanocortin System.

Current topics in microbiology and immunology·2026
Same journal

Resolution of Skeletal Muscle Inflammation: Role of Specialized Pro-resolving Lipid Mediators in the Recovery from Exercise, Injury, and Disease.

Current topics in microbiology and immunology·2026
Same journal

Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Strains.

Current topics in microbiology and immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

Adoptive T-Cell Immunotherapy.

Stephen Gottschalk1, Cliona M Rooney2

  • 1Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Baylor College of Medicine, 1102 Bates Street, Suite 1770, Houston, TX, 77030, USA. smg@bcm.edu.

Current Topics in Microbiology and Immunology
|October 3, 2015
PubMed
Summary
This summary is machine-generated.

Epstein-Barr virus (EBV)-specific T cells (EBVSTs) show promise for preventing and treating EBV-associated cancers. Ongoing research aims to enhance EBVST effectiveness against various EBV-driven malignancies.

Keywords:
CancerEBVGene transferImmunotherapyT‐Cell therapy

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.6K

Related Experiment Videos

Last Updated: Apr 1, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
11:31

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

8.6K

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Epstein-Barr virus (EBV) is linked to diverse cancers, including lymphomas and carcinomas.
  • Tumor antigen expression varies with EBV latency patterns, impacting treatment strategies.

Purpose of the Study:

  • To review the role of EBV-specific T cells (EBVSTs) in managing EBV-associated malignancies.
  • To explore current strategies for enhancing EBVST efficacy.

Main Methods:

  • Review of clinical studies on EBVSTs for prophylaxis and therapy.
  • Analysis of different EBV latency types and their associated antigens.
  • Examination of novel approaches to improve EBVST antitumor activity.

Main Results:

  • EBVSTs are most effective for post-transplant lymphoproliferative disease (PTLD) in hematopoietic stem-cell transplant (HSCT) recipients (type 3 latency).
  • EBVSTs show therapeutic potential for PTLD post-solid organ transplant and certain lymphomas/carcinomas (type 2 latency).
  • Strategies to enhance EBVSTs include antigen-specific T-cell expansion and genetic modification.

Conclusions:

  • EBVSTs are a valuable tool for combating EBV-positive malignancies.
  • Further research and combination therapies are crucial for optimizing EBVST treatment outcomes.
  • EBVSTs are expected to become a key component of future cancer treatment regimens.